Trial · NCT02004262
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Primary Cohort: Overall Survival (OS) Censored at 138 Deaths (ITT Set) | Primary Cohort: Cy/GVAX + CRS-207 | 3.8 | 95% Confidence Interval 2.9 to 5.3 | months | |
| Primary Cohort: Overall Survival (OS) Censored at 138 Deaths (ITT Set) | Primary Cohort: CRS-207 | 5.4 | 95% Confidence Interval 4.2 to 6.9 | months | |
| Primary Cohort: Overall Survival (OS) Censored at 138 Deaths (ITT Set) | Primary Cohort: Chemotherapy | 4.6 | 95% Confidence Interval 4.2 to 5.8 | months | |
| Primary Cohort: OS (All Data, FAS) | Primary Cohort: Cy/GVAX + CRS-207 | 4.2 | 95% Confidence Interval 3.0 to 5.4 | months | |
| Primary Cohort: OS (All Data, FAS) | Primary Cohort: CRS-207 | 5.2 | 95% Confidence Interval 4.2 to 6.3 | months | |
| Primary Cohort: OS (All Data, FAS) | Primary Cohort: Chemotherapy | 4.7 | 95% Confidence Interval 3.8 to 6.0 | months | |
| 2nd-line Cohort: OS (All Data, FAS) | 2nd-line Cohort: Cy/GVAX + CRS-207 | 4.6 | 70% Confidence Interval 3.9 to 6.0 | months | |
| 2nd-line Cohort: OS (All Data, FAS) | 2nd-line Cohort: CRS-207 | 4.0 | 70% Confidence Interval 3.4 to 6.7 | months | |
| 2nd-line Cohort: OS (All Data, FAS) | 2nd-line Cohort: Chemotherapy | 6.9 | 70% Confidence Interval 4.2 to 12.3 | months | |
| Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen | Pooled Cohort: Cy/GVAX + CRS-207 | Serious AEs | 44 | Participants | |
| Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen | Pooled Cohort: CRS-207 | Serious AEs | 32 | Participants | |
| Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen | Pooled Cohort: Chemotherapy | Serious AEs | 15 | Participants | |
| Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen | Pooled Cohort: Cy/GVAX + CRS-207 | Total AEs | 94 | Participants | |
| Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen | Pooled Cohort: CRS-207 | Total AEs | 87 | Participants | |
| Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen | Pooled Cohort: Chemotherapy | Total AEs | 52 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02004262/results